Human papillomavirus (HPV) Associated Cancer - Pipeline Review, H1 2014


Global Markets Direct’s, ‘Human papillomavirus (HPV) Associated Cancer - Pipeline Review, H1 2014’, provides an overview of the Human papillomavirus (HPV) Associated Cancer’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Human papillomavirus (HPV) Associated Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Human papillomavirus (HPV) Associated Cancer and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. 



  • The report provides a snapshot of the global therapeutic landscape of Human papillomavirus (HPV) Associated Cancer
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Human papillomavirus (HPV) Associated Cancer and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Human papillomavirus (HPV) Associated Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Human papillomavirus (HPV) Associated Cancer pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to Buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Human papillomavirus (HPV) Associated Cancer
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Human papillomavirus (HPV) Associated Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Human papillomavirus (HPV) Associated Cancer Overview 9
Therapeutics Development 10
Pipeline Products for Human papillomavirus (HPV) Associated Cancer - Overview 10
Pipeline Products for Human papillomavirus (HPV) Associated Cancer - Comparative Analysis 11
Human papillomavirus (HPV) Associated Cancer - Therapeutics under Development by Companies 12
Human papillomavirus (HPV) Associated Cancer - Therapeutics under Investigation by Universities/Institutes 15
Human papillomavirus (HPV) Associated Cancer - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Unknown Stage Products 19
Human papillomavirus (HPV) Associated Cancer - Products under Development by Companies 20
Human papillomavirus (HPV) Associated Cancer - Products under Investigation by Universities/Institutes 21
Human papillomavirus (HPV) Associated Cancer - Companies Involved in Therapeutics Development 22
Merck & Co., Inc. 22
3SBio Inc. 23
Transgene SA 24
Prima BioMed Ltd. 25
Antigen Express, Inc. 26
Bionor Pharma ASA 27
PDS Biotechnology Corporation 28
Onconova Therapeutics, Inc. 29
Genexine, Inc. 30
Etubics Corporation 31
iBio, Inc. 32
Sirnaomics, Inc. 33
Cancer Therapeutics CRC Pty Ltd 34
EyeGene, Inc. 35
Vaccibody AS 36
VLP Biotech, Inc. 37
Coridon Pty Ltd 38
Human papillomavirus (HPV) Associated Cancer - Therapeutics Assessment 39
Assessment by Monotherapy Products 39
Assessment by Target 40
Assessment by Mechanism of Action 42
Assessment by Route of Administration 44
Assessment by Molecule Type 46
Drug Profiles 49
V-503 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
rigosertib sodium - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
TG-4001 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
P16_37-63 Vaccine - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
PDS-0101 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
EG-HPV - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
GX-188-E - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
HPV Therapeutic Vaccine - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
SSS-08 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Vaccine To Target HPV E7 Protein For Human Papillomavirus Associated Cancer - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
HPV-Head and Neck Cancer Vaccine - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
AEH-10p - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Human Papillomavirus Vaccine - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
HPV Vaccine - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
VB-1016 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
STP-909 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Anti-E6 Protein Antibodies - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Anti-E7 Protein Antibodies - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
CerviVax - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Lac-E7 Vaccine - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
STP-911 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Ubiquitin E3 Ligase E6AP Inhibitor Program - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Peptides to Inhibit HPV E6 Protein for Cervical Cancer - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
Vacc-HPV - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Human papillomavirus (HPV) Associated Cancer - Recent Pipeline Updates 78
Human papillomavirus (HPV) Associated Cancer - Dormant Projects 88
Human papillomavirus (HPV) Associated Cancer - Product Development Milestones 89
Featured News & Press Releases 89
May 08, 2014: New Cervarix two-dose data demonstrate potential for increased flexibility of vaccine administration schedule 89
Mar 05, 2014: Generex Subsidiary Antigen Express Receives Patents for Vaccines Targeting HPV Induced Cancers and Influenza 90
Feb 27, 2014: Gardasil: New 2-dose Schedule Granted Positive CHMP Opinion for Europe's Leading HPV Vaccine 90
Nov 04, 2013: Merck’s Investigational 9-valent HPV Vaccine, V503, Prevented 97 Percent of Cervical, Vaginal and Vulvar Pre-cancers Caused by Five Additional HPV Types, in Phase III Study 91
Oct 07, 2013: CEL-SCI Announces Cooperative Research and Development Agreement for Multikine with US Navy 93
Sep 05, 2013: Advaxis Lead Product Candidate ADXS-HPV in Combination with PD-1 Antibody Significantly Improves Immune and Therapeutic Efficacy in Preclinical Study 94
Aug 14, 2013: Advaxis’ ADXS-HPV Granted Orphan Drug Designation for Treatment of HPV-Associated Anal Cancer 94
Aug 07, 2013: GSK submits Cervarix two dose schedule application in EU 95
Apr 16, 2013: PDS Biotechnology's New Cancer Immunotherapy PDS0101 Set To Enter Clinical Trials 95
Feb 21, 2013: CHMP Adopts Positive Opinion Recommending Variation To Terms Of Marketing Authorization For GSK's Cervarix 96
Appendix 97
Methodology 97
Coverage 97
Secondary Research 97
Primary Research 97
Expert Panel Validation 97
Contact Us 98
Disclaimer 98